Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Circ Res ; 90(4): 413-9, 2002 Mar 08.
Article in English | MEDLINE | ID: mdl-11884370

ABSTRACT

Although estradiol (E(2)) has been recognized to exert several vasculoprotective effects in several species, its effects in mouse vasomotion are unknown, and consequently, so is the estrogen receptor subtype mediating these effects. We investigated the effect of E(2) (80 microg/kg/day for 15 days) on NO production in the thoracic aorta of ovariectomized C57Bl/6 mice compared with those given placebo. E(2) increased basal NO production. In contrast, the relaxation in response to ATP, to the calcium ionophore A23187, and to sodium nitroprusside was unaltered by E(2), whereas acetylcholine-elicited relaxation was decreased. The abundance of NO synthase I, II, and III immunoreactive proteins (using Western blot) in thoracic aorta homogenates was unchanged by E(2). To determine the estrogen receptor (ER) subtype involved in these effects, transgenic mice in which either the ERalpha or ERbeta has been disrupted were ovariectomized and treated, or not, with E(2). Basal NO production was increased and the sensitivity to acetylcholine decreased in ERbeta knockout mice in response to E(2), whereas this effect was abolished in ERalpha knockout mice. Finally, these effects of E(2) on vasomotion required long-term and/or in vivo exposure, as short-term incubation of aortic rings with 10 nmol/L E(2) in the isolated organ chamber did not elicit any vasoactive effects. In conclusion, this study demonstrates that ERalpha, but not ERbeta, mediates the beneficial effect of E(2) on basal NO production.


Subject(s)
Aorta, Thoracic/drug effects , Aorta, Thoracic/metabolism , Estradiol/administration & dosage , Nitric Oxide/metabolism , Receptors, Estrogen/metabolism , Adenosine Triphosphate/pharmacology , Animals , Biological Factors/metabolism , Body Weight/drug effects , Cyclooxygenase Inhibitors/pharmacology , Dose-Response Relationship, Drug , Drug Implants , Estrogen Receptor alpha , Estrogen Receptor beta , Female , In Vitro Techniques , Ionophores/pharmacology , Mice , Mice, Inbred C57BL , Mice, Knockout , Nitric Oxide Synthase/metabolism , Nitroprusside/pharmacology , Ovariectomy , Receptors, Estrogen/deficiency , Receptors, Estrogen/genetics , Uterus/drug effects , Vasoconstriction/drug effects , Vasodilation/drug effects , Vasodilator Agents/pharmacology
2.
Proc Natl Acad Sci U S A ; 99(4): 2205-10, 2002 Feb 19.
Article in English | MEDLINE | ID: mdl-11854517

ABSTRACT

Two isoforms of estrogen receptor (ER) have been described: ERalpha and ERbeta. The initial gene targeting of ERalpha, consisting in the introduction of a Neo cassette in exon 1 [alphaERKO, hereafter called ERalpha-Neo KO (knockout)], was reported in 1993. More recently, another mouse deficient in ERalpha because of the deletion of exon 2 (ERalphaKO, hereafter called ERalpha-delta2 KO) was generated. In ovariectomized ERalpha-wild-type mice, estradiol (E(2)) increases uterine weight and basal production of endothelial nitric oxide (NO). Both of these effects are abolished in ERalpha-delta2 KO mice. In contrast, we show here that both of these effects of E(2) are partially (uterine weight) or totally (endothelial NO production) preserved in ERalpha-Neo KO. We also confirm the presence of two ERalpha mRNA splice variants in uterus and aorta from ERalpha-Neo KO mice. One of them encodes a chimeric ERalpha protein (ERalpha55), partially deleted in the A/B domain, that was detected in both uterus and aorta by Western blot analysis. The other ERalpha mRNA splice variant codes for an isoform deleted for the A/B domain (ERalpha46), which was detected in uterus of ERalpha-Neo KO, and wild-type mice. This protein isoform was not detected in aorta. The identification of these two N-terminal modified isoforms in uterus, and at least one of them in aorta, probably explains the persistence of the E(2) effects in ERalpha-Neo KO mice. Furthermore, ERalpha-Neo KO mice may help in the elucidation of the specific functions of full-length ERalpha (ERalpha66) and ERalpha46, both shown to be physiologically generated in vivo.


Subject(s)
Estradiol/pharmacology , Nitric Oxide/biosynthesis , Receptors, Estrogen/genetics , Receptors, Estrogen/physiology , Alternative Splicing , Animals , Aorta/metabolism , Blotting, Western , Dose-Response Relationship, Drug , Endothelium, Vascular/metabolism , Estrogen Receptor alpha , Exons , Female , Hypertrophy , Immunohistochemistry , Mice , Mice, Knockout , Models, Genetic , Mutagenesis, Insertional , Organ Size , Protein Isoforms , Protein Structure, Tertiary , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Uterus/drug effects , Uterus/metabolism , Uterus/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...